drugset / Trial / NCT04249583

Treatment of Moderate to Severe Glabellar Lines

NCT04249583

Phase 3 Completed 300 enrolled Galderma R&D
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.

Timeline

Start
2020-02-10
Primary completion
2020-08-07
Completion
2021-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin Protein / enzyme biologic Intramuscular

Indications

No indication recorded.